1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D002460:Cell Line; D002474:Cell-Free System; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D006224:Cricetinae; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D009316:National Institutes of Health (U.S.); D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats; D012513:Sarcoma, Experimental / Q000188:drug therapy; D013329:Structure-Activity Relationship; D014481:United States
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D002330:Carmustine